Natixis Advisors, L.P. Xenon Pharmaceuticals Inc. Transaction History
Natixis Advisors, L.P.
- $53.5 Billion
- Q4 2024
A detailed history of Natixis Advisors, L.P. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 23,554 shares of XENE stock, worth $916,486. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,554
Previous 27,158
13.27%
Holding current value
$916,486
Previous $1.07 Million
13.66%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding XENE
# of Institutions
218Shares Held
72MCall Options Held
152KPut Options Held
3.6K-
Avoro Capital Advisors LLC New York, NY5.67MShares$220 Million3.24% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.52MShares$176 Million1.73% of portfolio
-
Wellington Management Group LLP Boston, MA3.78MShares$147 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.91MShares$113 Million6.4% of portfolio
-
Janus Henderson Group PLC London, X02.87MShares$112 Million0.06% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.42B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...